Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aveo Eyes Role For Tivozanib In US Kidney Cancer Market, Against The Odds

Executive Summary

In the Phase III TIVO-3 study, tivozanib is associated with a trend toward adverse survival and trial has missing data issues.

Advertisement

Related Content

Pfizer Well-Placed To Lead First-Line Advanced RCC Market
Novartis Terminates Development Of Aveo Antibody
Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer
Aveo’s Tivozanib Troubles Reflect Perils Of Ex-U.S. Studies
Aveo’s Tivozanib Falls On Survival Data, Study Design Flaws

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel